Search Results - "Tutrone, R.F."

Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients by Furay, A, Nordquist, L.T, Dakhil, S.R, Green, N.B, Heath, E.I, Tutrone, R.F, Vogelzang, N.J, Armstrong, A.J, Cooperberg, M.R, Tyler, R.C, Whitmore, J.B, Higano, C.S

Get full text

1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114) by Avitia, J.W., Bailen, J.L., Shore, N.D., Tutrone, R.F., Nordquist, L.T., Walling, J., Peterson, L., Schotzinger, R., Moore, W.R.

Get full text

1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent by Markowski, M.C., Eisenberger, M., Pieczonka, C., Rodriguez, D., Barnette, K.G., Getzenberg, R.H., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S., Tutrone, R.F.

Get full text

Exosome-based testing enhances shared decision-making and improves patient risk stratification by Tutrone, R.F., Donovan, M., Torkler, P., Tadigotla, V., Alter, J., Noerholm, M., Skog, J., Mckiernan, J.

Get full text

626 NX-1207 for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) by Shore, N.D, Tutrone, R.F

Get full text

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH by Hansen, A.R., Probst, S., Tutrone, R.F., Osman, M.M., Delpassand, E.S., Nordquist, L.T., Viglianti, B.L., Michalski, J.M., Beauregard, J-M., Oz, O.K., Courtney, K., Jensen, J., Wu, W., Fleshner, N., Sartor, O., Chi, K.N., Tagawa, S.T.

Get full text

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide by Rathkopf, D.E., Smith, M.R., Ryan, C.J., Berry, W.R., Shore, N.D., Liu, G., Higano, C.S., Alumkal, J.J., Hauke, R., Tutrone, R.F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D.S., Yu, M.K., de Boer, C.J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H.I., Antonarakis, E.S.

“…Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation…”
Get full text

Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study by Tombal, B., Tutrone, R.F., Saad, F., George, D.J., Bailen, J.L., Cookson, M.S., Saltzstein, D.R., Brown, B., Lu, S., Shore, N.D.

Get full text

Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study by Tombal, B., Mehlhaff, B., Shore, N.D., George, D.J., Cookson, M.S., Saltzstein, D.R., Tutrone, R.F., Bailen, J.L, Brown, B., Langenberg, A.G.M., Lu, S., Fallick, M., Hanson, S., Saad, F.

Get full text